S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
OTCMKTS:HNSBF

Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis

$3.26
0.00 (0.00%)
(As of 03/1/2024 ET)
Today's Range
$3.26
$3.26
50-Day Range
$2.26
$3.30
52-Week Range
$2.26
$5.30
Volume
N/A
Average Volume
533 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

HNSBF stock logo

About Hansa Biopharma AB (publ) Stock (OTCMKTS:HNSBF)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

HNSBF Stock Price History

HNSBF Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Hansa Medical AB earnings: here's what to expect
Hansa Biopharma AB HNSA
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Hansa Biopharma half year report 2023
Hansa Biopharma provides Q1 update
Hansa Biopharma interim report January-March 2023
Hansa Biopharma AB (publ) (0RC7.IL)
Hansa Biopharma AB (publ) (HNSA.ST)
See More Headlines
Receive HNSBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hansa Biopharma AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:HNSBF
CIK
N/A
Fax
N/A
Employees
168
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Søren Tulstrup M.Sc (Age 59)
    President & CEO
    Comp: $15.26M
  • Mr. Donato Spota (Age 53)
    CFO & Senior VP
  • Dr. Christian Kjellman (Age 57)
    Senior VP & COO
  • Dr. Hitto Kaufmann Ph.D. (Age 53)
    Chief Scientific Officer
  • Ms. Eva-Maria Joed (Age 55)
    Vice President of Finance & Administration
  • Mr. Klaus Sindahl
    VP & Head of Investor Relations
  • Ms. Anne Säfström Lanner (Age 55)
    Senior VP & Chief Human Resources Officer
  • Mr. Emanuel Björne (Age 51)
    VP & Head of Business Development
  • Dr. Lena Winstedt (Age 55)
    Head of Science
  • Ms. Vincenza Nigro M.B.A.
    VP & Head of Medical Affairs














HNSBF Stock Analysis - Frequently Asked Questions

How have HNSBF shares performed in 2024?

Hansa Biopharma AB (publ)'s stock was trading at $2.2570 at the beginning of 2024. Since then, HNSBF shares have increased by 44.2% and is now trading at $3.2550.
View the best growth stocks for 2024 here
.

Are investors shorting Hansa Biopharma AB (publ)?

Hansa Biopharma AB (publ) saw a increase in short interest in February. As of February 15th, there was short interest totaling 572,600 shares, an increase of 7.7% from the January 31st total of 531,800 shares. Based on an average daily volume of 200 shares, the short-interest ratio is presently 2,863.0 days.
View Hansa Biopharma AB (publ)'s Short Interest
.

How do I buy shares of Hansa Biopharma AB (publ)?

Shares of HNSBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HNSBF) was last updated on 3/2/2024 by MarketBeat.com Staff